Your browser doesn't support javascript.
loading
Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling.
Zhou, Xiaoxiao; Zou, Haotian; Lutz, Michael W; Arbeev, Konstantin; Akushevich, Igor; Yashin, Anatoli; Welsh-Bohmer, Kathleen A; Luo, Sheng.
Afiliação
  • Zhou X; Department of Biostatistics & Bioinformatics Duke University Durham North Carolina USA.
  • Zou H; Department of Biostatistics & Bioinformatics Duke University Durham North Carolina USA.
  • Lutz MW; Division of Translational Brain Sciences Department of Neurology Duke University Medical Center Durham North Carolina USA.
  • Arbeev K; Social Science Research Institute Duke University Durham North Carolina USA.
  • Akushevich I; Social Science Research Institute Duke University Durham North Carolina USA.
  • Yashin A; Social Science Research Institute Duke University Durham North Carolina USA.
  • Welsh-Bohmer KA; Department of Psychiatry Duke University Durham North Carolina USA.
  • Luo S; Duke Clinical Research Institute (DCRI) Duke University Durham North Carolina USA.
Alzheimers Dement (N Y) ; 10(2): e12471, 2024.
Article em En | MEDLINE | ID: mdl-38835820
ABSTRACT

INTRODUCTION:

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deteriorations.

METHODS:

Longitudinal Item Response Theory (IRT) models were employed to analyze CDR domains in early-stage AD patients. Both unidimensional and multidimensional models were contrasted to elucidate the trajectories of cognitive and functional severities.

RESULTS:

We observed significant temporal increases in both cognitive and functional severities, with the cognitive severity deteriorating at a quicker rate. Tilavonemab did not demonstrate a statistically significant effect on the progression in either severity. Furthermore, a significant positive association was identified between the baselines and progression rates of both severities.

DISCUSSION:

While tilavonemab failed to mitigate impairment progression, our multidimensional IRT analysis illuminated the interconnected progression of cognitive and functional declines in AD, suggesting a comprehensive perspective on disease trajectories. Highlights Utilized longitudinal Item Response Theory (IRT) models to analyze the Clinical Dementia Rating (CDR) domains in early-stage Alzheimer's disease (AD) patients, comparing unidimensional and multidimensional models.Observed significant temporal increases in both cognitive and functional severities, with cognitive severity deteriorating at a faster rate, while tilavonemab showed no statistically significant effect on either domain's progression.Found a significant positive association between the baseline severities and their progression rates, indicating interconnected progression patterns of cognitive and functional declines in AD.Introduced the application of multidimensional longitudinal IRT models to provide a comprehensive perspective on the trajectories of cognitive and functional severities in early AD, suggesting new avenues for future research including the inclusion of time-dependent random effects and data-driven IRT models.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article